Patients prescribed cannabis-based medicinal products for inflammatory arthritis experienced sustained relief from chronic pain, sleep disruption, and reduced mobility over a two-year period, according to a study published in Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders.
Researchers analyzed clinical data from 192 patients enrolled in the UK Medical Cannabis Registry who were treated for chronic pain linked to conditions such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Participants completed standard health questionnaires before treatment and at intervals of one, three, six, 12, 18, and 24 months.
Two-Year Patient Outcomes
Inflammatory arthritis involves an abnormal immune response that causes persistent joint swelling, stiffness, and fatigue. The registry data showed steady gains across all evaluated metrics throughout the two-year timeline.
| Clinical Measure | Rate of Clinically Meaningful Improvement |
|---|---|
| Pain Severity | 62.5% of patients |
| Pain Interference (Daily Life) | 54.7% of patients |
| Sleep Quality | 45.3% of patients |
Anxiety scores dropped during the first three months of therapy and remained below baseline levels for the rest of the study period, though later variations did not meet statistical thresholds.
Adverse Events and Baseline Opioid Use
Managing chronic inflammatory pain often requires complex drug regimens. At the start of the study, 69 of the 192 participants were taking prescription opioids. More than half of the study group had used cannabis prior to joining the registry, while 29% were first-time consumers.
Over the two-year period, 27 patients (14% of the cohort) reported adverse events. Of the 296 recorded incidents, 43% were mild, 45% were moderate, and 13% were categorized as severe. No life-threatening complications occurred.
Observational Nature and Next Steps
The study authors noted key constraints in interpreting the data. Because the registry lacks a control group receiving a placebo, the findings cannot definitively prove that medical cannabis caused the reported health gains.
Instead, researchers highlighted that these two-year registry outcomes build a strong foundation for future randomized controlled trials to evaluate the efficacy of cannabis-based medicines in inflammatory arthritis management.
